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Essentials 
 Anticoagulation in patients with factor X deficiency is an evidence-poor area. 
 A patient with factor X deficiency was anticoagulated with warfarin followed by 
rivaroxaban. 
 Warfarin may be a safer anticoagulant option than rivaroxaban in hereditary factor X 
deficiency. 
 A baseline coagulation screen should be performed prior to commencement of 
anticoagulation. 
 
Abstract 
We report a case of a previously undiagnosed factor X deficiency in an 83-year old man, who 
had no previous bleeding history despite multiple haemostatic challenges. He was 
anticoagulated with warfarin for atrial fibrillation (AF) without bleeding complications; 
however, major haemorrhage occurred soon after a switch to rivaroxaban. 
 
Case Description 
An 83-year old man presented to the anticoagulation clinic requesting a switch from warfarin to 
rivaroxaban, due to a poor time in therapeutic range (TTR) and the inconvenience of INR 
monitoring. He had been on warfarin for 15 years for stroke prevention in the context of AF. His 
CHA2DS2 VASc score was 3 (age >75 years and history of ischaemic heart disease) equating to a 
3.2% annual stroke risk [1]. His target INR range was 2.0-3.0 with a TTR of only 44%, spending 
approximately 20% of the time supra-therapeutic. He required a warfarin dose of 1-2mg daily 
with INR monitoring every 2-3 weeks. His previous medical history included laryngeal 
carcinoma, coeliac disease, hypercholesterolemia, coronary artery bypass grafting and chronic 
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kidney disease. The estimated creatinine clearance (Cockcroft-Gault) was 50 ml/min.  He had no 
family or personal bleeding history either prior to, or whilst on, warfarin.  
 
Warfarin was stopped, and when the INR had fallen below 2.5 he was switched to rivaroxaban 
20mg once daily, and routinely reviewed after 3 weeks. The 6-hour rivaroxaban level, was 
365ng/ml (expected range at this time point: 123-318ng/ml) [2]. Rivaroxaban concentrations 
were determined by anti-Xa activity using the STA anti-Xa assay (Diagnostica Stago, Asnieres-
sur-Seine, France). Six weeks following commencement of rivaroxaban he presented to the 
Emergency Department with continuous bleeding from the mouth and gums, which had lasted 
for over 14 hours. Rivaroxaban was stopped, and he was prescribed tranexamic acid 
mouthwash. Admission bloods revealed haemoglobin 121 g/L (7.51 mmol/L), platelets 195 x 
109/L, creatinine 110 umol/L, urea 8.5 mmol/L, INR 5.53 and APTT ratio 1.73. The following 
day, the haemoglobin had fallen to 96 g/L (5.95 mmol/L), indicating a major haemorrhage 
according to the International Society on Thrombosis and Haemostasis (ISTH) definition [3]. At 
this point, INR was 2.41 and the APTR had normalized. A rivaroxaban level taken at 30 hours 
post dose was reported as 119 ng/ml.  He was discharged home the following day without 
anticoagulation. Two weeks later the INR was still prolonged at 1.54 and a 50:50 mixing study 
completely corrected, raising the suspicion of an underlying coagulation factor deficiency. The 
coagulation factor X level was measured at 34 u/dl (50-150 u/dl) consistent with mild factor X 
deficiency, which at this level is unlikely to cause a bleeding phenotype. Mutation analysis 
confirmed heterozygosity for a c.400G>A substitution in exon 5 of the factor X gene.  
 
Factor X deficiency is an autosomal recessive bleeding disorder with a prevalence of 1:1 000 
000 [4]. It usually presents with mucocutaneous bleeding, particularly heavy menstrual 
bleeding in women [5]. His treatment options were reviewed in light of the diagnosis of mild 
factor X deficiency. It was decided, based on his previous experience of having taken warfarin 
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safely for 15 years, to recommence this. An alternative option would have been to use the direct 
thrombin inhibitor dabigatran. In over a year of subsequent follow up, there have not been any 
further bleeding problems reported. Factor X level measured whilst on warfarin was 12 u/dl.  
 
There are a number of potential reasons why bleeding occurred on rivaroxaban but not on 
warfarin. The patient was in effect overdosed with rivaroxaban as the pre-existing factor X was 
already low. In contrast, the residual factor X activity (12 u/dl) on warfarin is likely to be 
sufficient to maintain adequate haemostasis and confer protection against bleeding. In addition, 
anticoagulation with warfarin results in a consistent reduction in thrombin generation over 
time, in contrast to the pharmacokinetic peaks and troughs in anticoagulant effect which is seen 
with relatively short-acting once-daily direct oral anticoagulants (DOACs) [6].  
 
Although DOACs have been shown to be associated with a lesser risk of intracranial 
haemorrhage than warfarin, mucocutaneous bleeding (for example heavy menstrual bleeding) 
is seen more frequently than with warfarin [7]. The presentation of our patient with oral 
bleeding was perhaps unsurprising, given the combination of anticoagulant and underlying 
condition.  
 
Bleeding disorders like factor X deficiency are rare but atrial fibrillation is highly prevalent in 
the elderly population and the issue of anticoagulation in such patients will occasionally arise 
and remains a poorly understood therapeutic area. Guidelines exist for anticoagulating 
haemophiliacs with factor VIII and IX deficiency and AF but such guidance does not exist in 
patients with rarer inherited bleeding disorders. Review of the notes did not reveal a baseline 
coagulation screen prior to the first initiation on warfarin 15 years previously. This might have 
revealed the diagnosis of factor X deficiency earlier and enabled a more ‘informed’ view of 
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anticoagulation options. Due to the lack of data regarding anticoagulation in such scenarios it 
might well have deterred usage of anticoagulation per se. There are several considerations to 
take in account when anticoagulating patients with rare bleeding disorders, including bleeding 
history, indication for anticoagulation therapy, intended duration of therapy and characteristics 
of the individual anticoagulant drug options [8]. Further, we are able to monitor DOAC levels if 
required, but the implications of such levels and the relation to thrombotic and bleeding risk 
remain incompletely understood [9]. 
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